Vous avez cherché: patients with 0 gi symptoms (Danois - Néerlandais)

s01ad local treatment of cmv retinitis in patients with aids
s01ad local treatment of cmv retinitis in patients with aids

c02kx01 symptomatic treatment of patients with pulmonary arterial hypertension
c02kx01 symptomatic treatment of patients with pulmonary arterial

b02bd04 treatment and prophylaxis of bleeding in patients with haemophilia b
b02bd04 treatment and prophylaxis of bleeding in patients with haemophilia b

l01ax03 indicated in the treatment of patients with recurrent malignant glioma
l01ax03 indicated in the treatment of patients with recurrent malignant glioma

n06dx01 treatment of patients with moderately severe to severe alzheimer disease
n06dx01 treatment of patients with moderately severe to severe alzheimer disease

l01xc03 treatment of patients with metastatic breast cancer whose tumour overexpress her2
- l01xc03 - treatment of patients with metastatic breast cancer whose tumour overexpress her2

long- term replacement therapy in patients with a confirmed diagnosis of fabry disease
long-term replacement therapy in patients with a confirmed diagnosis of fabry disease

j05a ttreatment of hiv infected patients with early virological failure in combination with other anti hiv
j05a ttreatment of hiv infected patients with early virological failure in combination with other anti hiv

clinical investigation of medicinal products in the treatment of patients with chronic obstructive pulmonary disease
clinical investigation of medicinal products in the treatment of patients with chronic obstructive pulmonary disease

l01xx28 (temporary) treatment of patients with chronic myeloid leukemia (cml)
l01xx28 (temporary) treatment of patients with chronic myeloid leukemia (cml)

consolidation in adult patients with relapsed/ refractory acute promyelocytic leukaemia (apl),
leukaemia (apl),

b01ad10 treatment of adult patients with severe sepsis with multiple organ failure, when added to best standard care
b01ad10 treatment of adult patients with severe sepsis with multiple organ failure, when added to best standard care

concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment.
concept paper on the development of a cpmp note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment.

points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi)
points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi)

h01ax (proposed) treatment of patients with acromegaly who had an inadequte response to surgery and/ or radiation therapy and who did not respond to treatment with somatostatin analogues
h01ax (proposed) treatment of patients with acromegaly who had an inadequte response to surgery and/or radiation therapy and who did not respond to treatment with somatostatin analogues

irma 2- studiet (effects of irbesartan on microalbuminuria in hypertensive patients with type 2 diabetes mellitus) viste, at irbesartan 300 mg forsinker progression til klinisk proteinuri hos patienter med mikroalbuminuri.
20 het onderzoek naar de effecten van “ irbesartan op microalbuminurie in hypertensieve patiënten met type 2 diabetes mellitus (irma 2 )” toont aan dat irbesartan 300 mg de progressie tot uitgesproken proteïnurie in patiënten met microalbuminurie vertraagt.

titel på dokumentet points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi) note for guidance on the clinical development of medicinal products for the treatment of hiv infection.
titel document points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi) note for guidance on the clinical development of medicinal products for the treatment of hiv infection.

adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino- conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms: